Histogen Inc. HSTO
We take great care to ensure that the data presented and summarized in this overview for Histogen Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HSTO
View allLatest Institutional Activity in HSTO
Top Purchases
Top Sells
About HSTO
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Transactions at HSTO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2021
|
Richard W Pascoe President, CEO & Director |
BUY
Open market or private purchase
|
Direct |
20,000
+40.0%
|
$20,000
$1.14 P/Share
|
|
Dec 03
2020
|
Richard W Pascoe President, CEO & Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$10,000
$1.24 P/Share
|